Mounjaro side effects: what to expect during treatment

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist used for type 2 diabetes and weight management.

Like all GLP-1 based treatments, gastrointestinal side effects are the most frequently reported.

Very common (affecting more than 1 in 10 people):

• Nausea: the single most reported side effect, affecting up to 29% of patients in the SURMOUNT-1 trial at the 15 mg dose. It is usually worst during the first 4 to 8 weeks and during dose escalations
• Diarrhoea: reported by approximately 17% of patients. Stools may become looser or more frequent
• Reduced appetite: this is partly how Mounjaro supports weight loss, but some patients find the appetite suppression uncomfortable
• Constipation: affects around 11% of patients, as GLP-1 agonists slow gastric emptying

Common (affecting 1 in 10 to 1 in 100 people):

• Vomiting: usually occurs alongside nausea and settles with time
• Abdominal pain or discomfort: typically mild and self-limiting
• Dyspepsia and bloating: a feeling of fullness after smaller meals
• Injection site reactions: redness, itching or swelling at the injection site, generally mild
• Fatigue: some patients report tiredness in the early weeks of treatment

These effects are listed in the BNF and the European Medicines Agency product information. Most are dose-related and improve with continued use.

Serious side effects of Mounjaro are uncommon but require prompt medical attention if they occur.

Pancreatitis:

Acute pancreatitis has been reported with GLP-1 receptor agonists. Symptoms include severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting.

If you suspect pancreatitis, stop Mounjaro and seek urgent medical advice. The MHRA advises that patients should be informed about this risk before starting treatment.

Gallbladder problems:

Cholelithiasis (gallstones) and cholecystitis have been reported at higher rates in clinical trials, particularly with rapid weight loss. Symptoms include right upper abdominal pain, nausea and fever.

Severe gastrointestinal reactions:

In rare cases, patients may develop severe vomiting or diarrhoea leading to dehydration.

This is particularly important for patients taking other medicines that affect kidney function, as dehydration can precipitate acute kidney injury.

Hypoglycaemia:

When Mounjaro is combined with insulin or sulphonylureas, the risk of low blood sugar increases. Symptoms include shakiness, sweating, confusion and dizziness.

Dose adjustments to concurrent diabetes medicines may be needed.

Allergic reactions:

Rarely, serious hypersensitivity reactions including anaphylaxis have been reported. Seek emergency help if you develop swelling of the face, lips or throat, difficulty breathing or a widespread rash.

Contact your GP or call NHS 111 if you experience persistent or worrying symptoms. Call 999 for severe allergic reactions or breathing difficulties.

The majority of Mounjaro side effects are gastrointestinal and can be managed effectively with practical strategies.

Reducing nausea:

• Eat smaller, more frequent meals rather than three large ones. Smaller portions are easier to tolerate when gastric emptying is slowed
• Avoid fatty, greasy or spicy foods, which can worsen nausea
• Eat slowly and stop when you feel comfortably full rather than pushing through
• Stay upright for at least 30 minutes after eating
• Ginger tea or peppermint may provide mild relief for some patients

Managing diarrhoea:

• Stay well hydrated with water or oral rehydration solutions
• Avoid high-fibre foods temporarily if stools are very loose
• Probiotics may help some patients, though evidence is limited

Dealing with constipation:

• Increase fibre intake gradually with fruits, vegetables and wholegrains
• Drink plenty of water throughout the day
• Regular physical activity supports healthy bowel function
• Over-the-counter laxatives such as macrogol may be used short-term if needed

The importance of dose titration:

Mounjaro is started at 2.5 mg weekly and increased in 2.5 mg steps every 4 weeks.

This gradual approach, recommended in the BNF, allows the body to adjust and significantly reduces the severity of gastrointestinal symptoms. Do not skip dose steps or increase faster than advised.

While weight loss is often a desired outcome of Mounjaro treatment, the degree of appetite suppression and weight change can itself cause secondary effects.

Expected weight loss:

In the SURMOUNT-1 trial, patients on the highest dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks. This is a substantial change that brings both benefits and considerations.

Nutritional considerations:

• Reduced calorie intake may lead to deficiencies in vitamins and minerals if the diet is not well balanced
• Protein intake should be maintained to preserve lean muscle mass during weight loss. Aim for at least 1.2 g of protein per kilogram of body weight daily
• Iron, vitamin D and B12 levels should be monitored, especially in patients with significant appetite reduction

Metabolic benefits:

• HbA1c reduction: in the SURPASS trials, tirzepatide reduced HbA1c by up to 2.4 percentage points, reflecting improved blood sugar control
• Blood pressure: modest reductions in systolic blood pressure have been observed
• Lipid profile: improvements in triglycerides and cholesterol ratios have been reported

Hair thinning:

Some patients report increased hair shedding during rapid weight loss. This is known as telogen effluvium and is related to the caloric deficit rather than the medicine itself.

It is usually temporary and resolves once weight stabilises.

Discuss any concerns about nutrition or excessive weight loss with your prescriber or a registered dietitian.

Certain groups of patients may experience more pronounced side effects from Mounjaro and may need closer monitoring.

Patients with a history of gastrointestinal disease:

Those with gastroparesis, inflammatory bowel disease or a history of pancreatitis should use Mounjaro with caution. The slowing of gastric emptying can worsen pre-existing motility disorders.

Patients with kidney disease:

Dehydration from nausea, vomiting or diarrhoea can affect kidney function. The BNF advises monitoring renal function in patients with moderate to severe kidney impairment.

Patients on insulin or sulphonylureas:

The risk of hypoglycaemia is increased when Mounjaro is combined with these medicines. Proactive dose reduction of insulin or the sulphonylurea is often recommended when starting tirzepatide.

Patients with a history of gallbladder disease:

Rapid weight loss increases the risk of gallstones. Patients who have had previous gallbladder problems should be monitored and advised to report any right-sided abdominal pain.

Older adults:

Gastrointestinal side effects and associated dehydration may be more significant in older patients. Lower starting doses and careful monitoring are advisable.

Mounjaro is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception.

Mounjaro should be stopped at least 2 months before a planned pregnancy due to its long half-life.

Understanding the typical timeline of Mounjaro side effects can help set realistic expectations.

Weeks 1 to 4 (2.5 mg starting dose):

Most patients tolerate the starting dose well. Mild nausea and reduced appetite are the most common early effects. Some patients notice no side effects at all at this dose.

Weeks 5 to 12 (dose titration phase):

Side effects are most likely during dose increases. Each step up (to 5 mg, then 7.5 mg, then 10 mg) may trigger a temporary return of nausea or gastrointestinal discomfort.

This typically settles within 1 to 2 weeks at each new dose level.

Months 3 to 6 (maintenance phase):

By the time patients reach their maintenance dose, most gastrointestinal symptoms have significantly improved or resolved.

The body adapts to the slower gastric emptying and altered appetite signalling.

Beyond 6 months:

Long-term data from the SURMOUNT and SURPASS trials show that side effects continue to diminish over time.

The most common reason for discontinuation in clinical trials was gastrointestinal intolerance, but this affected fewer than 7% of patients on the highest dose.

Key points for the long term:

• Injection site reactions tend to resolve and rarely recur at the same site
• Weight loss typically plateaus after 12 to 18 months
• Regular blood tests to monitor kidney function, blood sugar and nutritional markers are advisable
• Attend scheduled reviews with your prescriber to assess ongoing benefit versus side effects